Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +6.62%8 OCF Margin % is -72.24% as of Dec. 2025. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Alamar Biosciences ranks worse than 82.97% on this metric.
The historical data trend for Alamar Biosciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences OCF Margin % Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
OCF Margin %
-219.61
-72.24
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
OCF Margin %
-219.61
-72.24
ALMR vs UFPT, BFLY, ENOV: OCF Margin % Comparison
For the Medical Devices subindustry, Alamar Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a OCF Margin % of -72.24% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alamar Biosciences and its competitors. According to the industry distribution chart, Alamar Biosciences ranks #677 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 83%.
Is Alamar Biosciences' OCF Margin % too high?
Alamar Biosciences' current OCF Margin % is -72.24%. Based on the distribution chart, Alamar Biosciences ranks #677 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' OCF Margin % compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #677 out of 816 companies for OCF Margin %. This places Alamar Biosciences in the lower half of its industry. The industry median OCF Margin % is 5.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.75, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current OCF Margin % is -72.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current OCF Margin % of -72.24%. The current OCF Margin % is -72.24%. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current OCF Margin % is -72.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
